{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:56:16Z","timestamp":1793519776451,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T00:00:00Z","timestamp":1279584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose.<\/jats:title>\n                    <jats:p>To report 5-year relative cancer survival probabilities conditional on having already survived \u22651 years after the initial diagnosis for 11 cancer sites, diagnosed during 1990\u20132001 and followed through 2006.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Analyses are based on 1,151,496 cancer cases in population-based cancer registries in the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>The 5-year relative conditional survival probability tended to improve with each year already survived. Improvement was greatest for more lethal cancers (e.g., lung or pancreas) and for cases with a more advanced stage at diagnosis. The 5-year relative survival probability conditional on already having survived 5 years exceeded 90% for locally staged prostate cancer, melanoma (whites only), breast cancer (females only), corpus uteri cancer, urinary bladder cancer, Hodgkin's lymphoma, rectal cancer, colon cancer, ovary cancer, and pancreatic cancer. Only lung cancer did not reach 90%. For these cancer sites combined, 5-year relative survival probability conditional on already having survived 5 years averaged about 85% for regionally staged disease, 68% for distant staged disease, and 87% for unknown staged disease. The 5-year relative conditional survival probability tended to be significantly lower among patients diagnosed at older ages, among males, among nonwhites, and among those diagnosed during 1990\u20131995 compared with later years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Conditional survival probability estimation provides further useful prognostic information to cancer patients, tailored to the time already survived since diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2009-0211","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T23:49:04Z","timestamp":1279669744000},"page":"873-882","source":"Crossref","is-referenced-by-count":111,"title":["Conditional Survival Among Cancer Patients in the United States"],"prefix":"10.1093","volume":"15","author":[{"given":"Ray M.","family":"Merrill","sequence":"first","affiliation":[{"name":"Department of Health Science at Brigham Young University, Provo, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Health Science at Brigham Young University, Provo, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,7,20]]},"reference":[{"key":"2021122207515200500_R1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2021122207515200500_R2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1470-2045(06)70794-X","article-title":"People's perceptions of cancer survivability: Implications for oncologists","volume":"7","author":"Donovan","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122207515200500_R3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.oraloncology.2008.04.012","article-title":"Conditional survival rates of buccal and tongue cancer patients: How far does the benefit go?","volume":"45","author":"Yang","year":"2009","journal-title":"Oral Oncol"},{"key":"2021122207515200500_R4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10120-007-0424-9","article-title":"Conditional survival in gastric cancer: A SEER database analysis","volume":"10","author":"Wang","year":"2007","journal-title":"Gastric Cancer"},{"key":"2021122207515200500_R5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ygyno.2008.01.033","article-title":"Conditional survival in ovarian cancer: Results from the SEER dataset 1988\u20132001","volume":"109","author":"Choi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2021122207515200500_R6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cncr.22563","article-title":"Conditional survival in head and neck squamous cell carcinoma: Results from the SEER dataset 1973\u20131998","volume":"109","author":"Fuller","year":"2007","journal-title":"Cancer"},{"key":"2021122207515200500_R7","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/cncr.21877","article-title":"Conditional survival of patients with diffuse large B-cell lymphoma","volume":"106","author":"Moller","year":"2006","journal-title":"Cancer"},{"key":"2021122207515200500_R8","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2003.04.521","article-title":"Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark","volume":"21","author":"Skuladottir","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207515200500_R9","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/1097-0142(20011015)92:8<2211::AID-CNCR1565>3.0.CO;2-W","article-title":"Conditional median survival of patients with advanced carcinoma: Surveillance, Epidemiology, and End Results data","volume":"92","author":"Kato","year":"2001","journal-title":"Cancer"},{"key":"2021122207515200500_R10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L","article-title":"The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, Epidemiology, and End Results (SEER) data","volume":"85","author":"Davis","year":"1999","journal-title":"Cancer"},{"key":"2021122207515200500_R11","first-page":"84","article-title":"Conditional survival in rectal cancer: A SEER database analysis","volume":"1","author":"Wang","year":"2007","journal-title":"Gastrointest Cancer Res"},{"key":"2021122207515200500_R12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1464-410X.2009.08524.x","article-title":"Paediatric testicular cancer: An updated review of incidence and conditional survival from the Surveillance, Epidemiology and End Results database","volume":"104","author":"Alanee","year":"2009","journal-title":"BJU Int"},{"key":"2021122207515200500_R13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.116.3.697","article-title":"Conditional survival among patients with carcinoma of the lung","volume":"116","author":"Merrill","year":"1999","journal-title":"Chest"},{"key":"2021122207515200500_R14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/BF02239430","article-title":"Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon","volume":"41","author":"Merrill","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"2021122207515200500_R15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdm127","article-title":"Prognosis for long-term survivors of cancer","volume":"18","author":"Janssen-Heijnen","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122207515200500_R16","first-page":"1117","article-title":"The Surveillance, Epidemiology and End Results Program: A national resource","volume":"8","author":"Hankey","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122207515200500_R17","volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program","author":"National Cancer Institute"},{"key":"2021122207515200500_R18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","article-title":"Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) Program","volume":"8","author":"Gloeckler Ries","year":"2003","journal-title":"The Oncologist"},{"key":"2021122207515200500_R19","first-page":"1","volume-title":"International Classification of Disease for Oncology","author":"Percy","year":"1990","edition":"Second Edition"},{"key":"2021122207515200500_R20","volume-title":"Surveillance Epidemiology and End Results","author":"National Cancer Institute, U.S. National Institutes of Health"},{"key":"2021122207515200500_R21","first-page":"28","article-title":"Cancer patient survival: Why use the relative survival rate","volume":"21","author":"Ries","year":"1995","journal-title":"The Abstract"},{"key":"2021122207515200500_R22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I","article-title":"The relative survival rate","volume":"76","author":"Henson","year":"1995","journal-title":"Cancer"},{"key":"2021122207515200500_R23","first-page":"87","volume-title":"Trends in Cancer Mortality in Industrial Countries","author":"Percy","year":"1990"},{"key":"2021122207515200500_R24","first-page":"101","article-title":"The relative survival rate: A statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"2021122207515200500_R25","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/cncr.24324","article-title":"Treatment and survival outcomes in young men diagnosed with prostate cancer: A population-based cohort study","volume":"115","author":"Lin","year":"2009","journal-title":"Cancer"},{"key":"2021122207515200500_R26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/sim.1597","article-title":"Regression models for relative survival","volume":"23","author":"Dickman","year":"2004","journal-title":"Stat Med"},{"key":"2021122207515200500_R27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0140-6736(93)92407-K","article-title":"Age as prognostic factor in premenopausal breast carcinoma","volume":"341","author":"Rochefordiere","year":"1993","journal-title":"Lancet"},{"key":"2021122207515200500_R28","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(00)02292-3","article-title":"Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?","volume":"355","author":"Aebi","year":"2000","journal-title":"Lancet"},{"key":"2021122207515200500_R29","doi-asserted-by":"crossref","first-page":"e7695","DOI":"10.1371\/journal.pone.0007695","article-title":"Breast cancer in young women: Poor survival despite intensive treatment","volume":"4","author":"Fredholm","year":"2009","journal-title":"PLoS One"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/8\/873\/41843287\/oncolo_15_8_873.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/8\/873\/41843287\/oncolo_15_8_873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:33:55Z","timestamp":1640151235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/8\/873\/6399390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,7,20]]},"published-print":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0211","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,8,1]]},"published":{"date-parts":[[2010,7,20]]}}}